Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics

Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant hypertension, because the agent did not achieve its co-primary endpoints in a phase III trial.

Cubist Pharmaceuticals said it plans to acquire privately held Calixa Therapeutics for $92.5 million in cash and up to $310 million in milestone payments. In the deal, expected to close by year's end, Cubist would obtain Calixa's rights to develop and commercialize the firm's Phase 2 antibiotic CXA-201, which is intended to treat common, serious Gram-negative infections.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.